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INFLAMMATION characteristically perturbs intestinal motility, causing both structural and functional alterations among the visceral regulatory and motor systems. Among these changes, hyperplasia of smooth muscle cells (SMC) is the principal cause of the thickening of the intestinal wall that is seen in both human disease and in animal models (5, 9, 23) . This reflects an increased muscle mass and potentially altered force production, at the same time as inflammation-induced damage to enteric neurons challenges the ability of the enteric nervous system to regulate contraction and relaxation (25, 34) . Whereas the intestinal smooth muscle cell (ISMC) is normally contractile and nonproliferative (i.e., differentiated), inflammation causes the ISMC to reenter the cell cycle, leading to rapid and substantial proliferation. In the trinitrobenzene sulfonic acid (TNBS) model of colitis in the rat, the most widely studied animal model of transmural T-helper type 1 predominant inflammation, we showed that ISMC number increased by 2 days after the onset of inflammation and caused a permanent threefold increase in ISMC number by 6 days postinitiation of colitis (25) . The factors responsible for this early and rapid hyperplasia are unknown.
Elsewhere, SMC hyperplasia is commonly observed in inflammatory diseases affecting the vascular and respiratory systems (2, 28, 30) . In general, the serum growth factor platelet-derived growth factor (PDGF) is an important determinant of the responses of mesenchymal cells in both vascular and fibrotic disorders, such as atherosclerosis, pulmonary hypertension, and pulmonary fibrosis (reviewed in Ref. 1) . A dimer of the polypeptides PDGF-A or PDGF-B, PDGF acts via two receptor-tyrosine kinases, PDGF-R␣, or PDGF-R␤, with functional evidence indicating that PDGF-AA acts via PDGF-R␣ while PDGF-BB acts via PDGF-R␤. Aspects of both acute and chronic inflammation are involved in driving the characteristic SMC growth that follows acute endothelial injury, but the common element is a response to PDGF released from activated platelets and immune cells (1) .
Relatively little is known of the role of PDGF in the adult intestine, although it is important in embryogenesis where there is the transient expression of both PDGF receptor subtypes in mouse intestinal mesenchyme (21) . There is limited knowledge of its role in intestinal SMC hyperplasia, beyond the pioneering work in cultured human ISMC of Graham et al. (11) . However, the broadly influential growth factor insulinlike growth factor-1 (IGF-1) stimulates growth in ISMC cell lines (19) , affects the growth and development of myofibroblasts and the epithelial cell compartment (27, 36) , as well as influences the development of the muscularis externa in vivo (35) . IGF-1 also has widespread effects in pathological conditions such as cardiovascular disease and hyperglycemia-induced vascular SMC proliferation (7, 22, 42) . The receptor for IGF-1 is present in cultured rat colonic smooth muscle cells (41) , and recent work has identified an involvement of IGF-1 in established TNBS colitis in the rat, showing increased IGF-1 receptor phosphorylation and increased basal rates of proliferation in cultures of ISMC isolated from animals at day 7 of inflammation (12) . This study identified an unsuspected consequence of the initial hyperplasia but did not identify the causative factors for that event.
in vitro experiments have long established that continued growth of vascular SMC in culture causes a progressive loss of the contractile phenotype and acquisition of a synthetic or proliferative phenotype with concomitant increase in extracellular matrix deposition (reviewed in Ref. 15) . In vivo, ISMC that arise in inflammation-driven hyperplasia may be prone to a continued mitotic response and ultimately a phenotypic alteration that could lead to the eventual formation of intestinal strictures (in severely inflamed regions of intestine), as seen in both the TNBS model (26) and in chronic human disease in inflammatory bowel disease (IBD) (10) .
We recently identified a mechanism of neural regulation of CSMC proliferation in vitro and proposed that inflammationinduced damage might increase the responsiveness of CSMC to growth factors in vivo (29) . Now we hypothesized that the growth factors PDGF and IGF-1 could be important in the early hyperplastic response in colitis, as it is in other smooth muscle systems, and studied this both in vitro and in the TNBS model of colitis in the rat. Since the nature of the ISMC may vary between the initial and subsequent stages of colitis and is likely to be strongly affected by growth in vitro, ISMC were enzymatically isolated from the control rat colon as described previously (38) to develop a primary tissue culture model for the study of the onset of mitotic responsiveness in initially contractile, highly differentiated ISMC over the first few days in vitro.
METHODS

Animals.
Adult male Sprague-Dawley rats were obtained from Charles River (Quebec, Canada) and housed in pairs in microfilterisolated cages for at least 5 days before use with free access to food and water. Animals were euthanized by cervical dislocation under isoflurane anesthesia at various times after the initiation of colitis. All procedures received prior approval by the University Animal Care Committee of Queen's University.
Induction of colitis. Colitis was induced by instillation of 500 l of 200 mM TNBS (Fluka) dissolved in 50% ethanol into the colon 8 cm proximal to the anus, while the animal was under light anesthesia by inhalation of isoflurane as previously described (38) .
Tissue preparation. The inflamed region of the middescending colon (or corresponding region in control animals) was identified and removed, fixed in 4% neutral buffered formalin (NBF) for 24 h, followed by routine embedding in paraffin. Cross-sections of 4 m were processed for immunocytochemistry as described below. In all cases, the presence of inflammation was verified using the independent criteria of weight loss and histological evaluation of transmural inflammation.
Whole mount preparations were also obtained from control animals as described previously (24) . A segment of middescending colon was opened along the mesenteric border and pinned mucosal side up in Hanks' saline with 10 mM HEPES (Hanks' HEPES, pH 7.0). The mucosa and submucosa were removed, and the circular smooth muscle layer was removed, fixed in NBF for 1 h, and processed for immunocytochemistry as described below.
Isolation of primary CSMC. CSMC were obtained as previously described with slight modifications (38) . Briefly, small strips of circular smooth muscle tissue were removed from the middescending colon using fine dissection in HEPES-buffered Hanks' saline (pH 7.35), after removal of the mucosa and submucosa. These were enzymatically dissociated as described (37, 38) with muscle strips placed in a HEPES-buffered (HPSS) digestion solution containing papain (0.5 mg ml/ml; Sigma), BSA (1 mg/ml), dl-dithiothreitol (1 M; Sigma), and collagenase type-F (0.5 mg/ml; Sigma) and incubated at 4°C for 2 h, and then room temperature for 1 h and finally 37°C for 1 h. The solution was replaced with culture media with 5% fetal calf serum (Invitrogen), and cells were gently triturated to produce a suspension of viable individual CSMC. Cells were then seeded in 24-well plates on either plastic wells (for immunoblotting or [ 3 H]thymidine assay) or on rat tail collagen-coated glass coverslips (for immunocytochemistry). Pilot studies found that cohort cultures established on laminin, collagen, or fibronectin showed similar responses to growth factors, and collagen was used in subsequent experiments. Phase contrast microscopy (Olympus IMT-2) was used to examine cell morphology of CSMC at various times following isolation. Cell viability was evaluated using calcein-AM (Molecular Probes) and trypan blue staining. Image acquisition, and analysis was carried out using Image ProPlus 6.0 (Media Cybernetics).
RT-PCR and quantitative RT-PCR. Total RNA was isolated from freshly isolated intestinal smooth muscle cells or cells cultured for 4 days in DMEM with 5% FCS using an RNeasy kit (Qiagen) according to the manufacturer's protocol. Approximately 1 g of total RNA after DNase I treatment was converted into cDNA using the iScript RT kit (Bio-Rad). PCR was used to check the expression of PDGF-R␣ and PDGF-R␤ using GAPDH as the internal control. Primer sequences were PDGF-R␣ forward, 5=-ATGTTTCTAGACTCGCAGCTCA-3= and reverse, 5=-ATAAACAAAGGCAGTGATACAG-3=, yielding an amplicon of 692 bp; PDGF-R␤ forward, 5=-CAACATTTCGAGCACCTTTGT-3=, and reverse, 5=-AGGGCACTCCGAAGAGGTAA-3=, yielding an amplicon of 677 bp; GAPDH forward, 5=-TGACAACTTTGGCATCGTGG-3=, and reverse, 5=-TACTCCTTGGAGGCCATGT-3=, producing a 513 bp amplicon. The PCR conditions were 94°C for 4 min, then 94°C for 30 s, 55°C for 30 s, and 72°C for 45 s (30 cycles), and 72°C for 10 min as final extension. The PCR products were resolved on a 1% agarose gel and imaged using Image Pro Plus 6.0 software (Media Cybernetics).
For quantitative RT-PCR, cDNA from freshly isolated or cultured CSMC (ϳ150 -200 ng) was taken for real-time PCR using iTaq Fast SYBR Green supermix with ROX (Bio-Rad) in an Applied Biosystems 7500 Real-Time PCR instrument (Applied Biosystems). Primer sequences were PDGF-R␤ forward, 5=-AATGACCACGGCGAT-GAGA-3= and reverse, 5=-TCTTCCAGTGTTTCCAGC AGC-3=; GAPDH forward 5=-TGCACCACCAACT GCTTAG-3= and reverse 5=-GATGCAGGGATGATGTTC-3=. Dissociation curve analysis following each amplification reaction confirmed the specificity of amplification. RNA expression levels were determined by Ct analysis settings of 7500 System Sequence Detection Software v1.3 using the ⌬⌬Ct comparative method of relative quantification. Results were expressed as fold change relative to the control (day 0) cells.
Immunocytochemistry. Immunocytochemistry of CSMC in culture was carried out as previously described (4) . Cells were fixed in 4% NBF and then blocked for 1 h at room temperature in 0.2% Tween-20 in PBS containing 1% goat serum to prevent nonspecific antibody labeling. This was followed by incubation with antibodies to ␣-smooth muscle actin (1/500; DAKO), desmin (1/250; Sigma), PDGF-R␤ (1/250; Cell Signaling Technology Ab28E1), or IGF-R1 (1/250; Cell Signaling Technology) overnight at 4°C. After incubation in appropriate ALEXA-linked secondary antibodies, cells were incubated with 1 g/ml Hoechst 33342 for 30 s to label nuclei. For determination of cell phenotype in freshly isolated cell suspensions, aliquots of cells were dried onto glass slides and then prepared as above. These preparations and primary cultures were examined for the presence of glia, neurons, and interstitial cells of Cajal using antibodies to glial fibrillary acidic protein (GFAP) or S-100 (Sigma), HuD (Molecular Probes), or c-kit (Cedarlane), respectively.Freshly isolated cells from the neonatal rat small intestine were used as a positive control for c-kit staining.
To examine PDGF-R/IGF-R mobilization, preconfluent primary CSMC were used (days 6 -8). PDGF-BB (Peprotech) or IGF-I (Cedarlane) were added 30 min before fixation and processed as indicated above. All antibodies were diluted in antibody diluting buffer (DAKO).
To evaluate uptake of bromo-deoxyuridine (BrdU) in vitro, cultures were first serum deprived for 3 days before exposure to potential mitogens. Seventeen hours after mitogen addition, BrdU was added for 4 h (20 l/ml of a 0.5 mM solution of BrdU), followed by fixation in methanol-acetone (50:50) for 5 min. After being washed in PBS, cultures were exposed to 2 N HCl for 2 h, neutralized in NaBO4 (0.04 g/ml), washed in PBS, and processed for immunocytochemistry with anti-BrdU antibodies for 4 h at room temperature (1/500; BU-33, Sigma). Secondary detection was for 30 min at room temperature (ALEXA 488-goat anti-mouse, 1/1,000), followed by nuclear staining as above. BrdU labeling was quantified by direct counting of positive nuclei in fields selected randomly at ϫ20 objective magnification (6 fields/culture; 2-3 cultures per experiment) and comparison with the number of total nuclei obtained from Hoechst labeling. Each experiment was repeated four times and the outcomes averaged.
For immunocytochemistry of control and inflamed tissue, paraffin cross-sections (4 m) or whole mount preparations were blocked as above, followed by overnight labeling at 4°C with antibodies to PDGF-R␤, smooth muscle actin, desmin, or platelet endothelial cell adhesion molecule-1 (PECAM) (1/2,000; Cell Signaling Technology). This was followed by 1 h incubation with appropriate ALEXA 555-or ALEXA 488-labeled secondary antibodies. Since the PECAM antibody is of goat origin and required an anti-goat secondary antibody, dual-labeling immunocytochemistry with PDGF-R␤ required a modified protocol; PECAM labeling (primary and secondary antibody incubations) were completed before PDGF-R␤ labeling and followed by treatment with Hoechst 33342. Staining was visualized with fluorescence microscopy (Olympus BX51).
To determine the number of PDGF-R␤-positive CSMC, complete cross sections of control or inflamed colon were labeled using the PDGF-R␤ antibody and nuclei stained nonspecifically with Hoechst 33342. Images were taken from six random, nonoverlapping fields from sections of each of Ն3 animals per time point (ϳ500 -800 cells total per time point), and CSMC were identified based on elongated nuclear morphology (38) . The proportion of PDGF-R␤ immunoreactive CSMC was expressed as percentage of total CSMC. Some sections were dual-labeled with anti-PECAM antibodies and imaged using laser confocal microscopy (Olympus IX-70 and Fluoview F-300).
Immunoblotting. To examine the expression of PDGF-R␤, IGF-R, or downstream signaling effector proteins, immunoblotting was performed on confluent primary CSM. After rinsing cells in serum-free culture media, fresh serum-free culture media was added, and cells were incubated for 72 h. Cells were then incubated with PDGF-BB (50 ng/ml), IGF-1 (50 -100 ng/ml), or vehicle for 15 min and then lysed. Proteins were resolved by SDS-PAGE and transferred to polyvinyldifluoride membrane using a semidry transfer apparatus (Bio-Rad). Blots were incubated for 1 h at room temperature with blocking solution (5% nonfat milk in Tris-buffered saline containing 0.2% Tween-20). The membrane was then incubated with primary antibodies to PDGF-R␤, phosphorylated-PDGF-R␤, IGF-R, phosphorylated-IGF-R, Akt, phosphorylated-Akt, ERK, or phosphorylated-ERK overnight at 4°C (antibodies to phosphoproteins were from Cell Signalling and used at 1/1,000). This was followed by 2 h incubation in goat anti-rabbit horseradish peroxidase at room temperature. Bands were visualized using BioMax film after incubation in chemiluminescent substrate (Super Signal, Pierce). Samples were subsequently reprobed with antibodies to ␣-tubulin (Sigma; 1/5,000) to ensure equal protein loading.
Immunoprecipitation. For some experiments, cells isolated from colons removed from control animals or animals treated with TNBS 2 days earlier were treated with IGF-1 or PDGF-BB (100 ng/ml) or vehicle. Cells were lysed and immunoprecipitated for IGF-R or PDGF-R␤ by using the manufacturer's protocol. Briefly, 200 g protein was made up to a final volume of 200 l with lysis buffer and 4 l anti-IGF-R or PDGF-R␤ was added. After an overnight incubation at 4°C, 20 l of protein G-conjugated agarose beads (Pierce Biolynx, Fisher) were added and incubated at 4°C for 2 h. Beads were then washed five times with lysis buffer. Samples were then immunoblotted using either pIGF-R and IGF-R or pPDGF-R␤ and PDGF-R␤ as described above. Proliferation assay. To evaluate the growth responses to PDGF and IGF, [ 3 H]thymidine incorporation assays were performed on primary CSMC at 7-12 days in vitro. Cultures were incubated in serum-free media for 72 h before the medium was replaced with either culture media alone (control) or with media containing fetal calf serum or EGF, bFGF, IGF-1, PDGF-AA, or PDGF-BB (PeproTech; Cedarlane). After a 17-h incubation, [ 3 H]thymidine was added for 5 h, and cells were processed for scintillation counting (4). Counts were normalized to cohort negative controls and expressed as fold increases over control. In some cases, the roles of ERK and AKT phosphorylation were tested by pretreatment with either PD-98059 or LY-294002 for 60 min before stimulation with PDGF-BB and subsequent assay as above. Maximum doses for each inhibitor were determined by limits of solubility (PD-98059, 100 M) or cytotoxicity (LY-294002, 1 M), and control experiments showed no effect of the carrier (DMSO) alone.
To confirm growth factor-induced proliferation, cohort plates were set up as above using 100 ng/ml of growth factor incubated for 72 h poststimulus and counted manually. Counts were normalized to cohort negative controls and expressed as fold increase over control.
Solutions. Solution compositions were as follows: HPSS-digestion solution (in mM: 125 NaCl, 10 glucose, 10 Na-HEPES, 1 MgCl 2, 4 KCl, 1 CaCl2, 0.25 EDTA, and 10 taurine, pH 7.2) with additional CaCl2 (2.5 mM), papain (0.25 g/ml), bovine serum albumin (BSA; 0.5 g/ml), dl-dithiothreitol (DTT; 1 M), and collagenase type-F (0.25 mg/ml). Culture medium was Dulbecco's modified essential media with penicillin and streptomycin (Sigma) and ciprofloxacin (Bayer).
The composition of the lysis buffer was (in mM) 10 Tris·HCl, 150 NaCl, 5 EDTA, 0.2% Triton X-100, and 0.5% sodium deoxycholate; pH 8.0 with leupeptin (10 M), aprotinin (10 M), phenylmethylsulfonyl fluoride (1 mM), and orthovanadate (1 mM). After 30 min incubation at 4°C, the tissue was centrifuged for 10 min at 13,000 rpm in a refrigerated microcentrifuge. The supernatant was split into aliquots and stored at Ϫ70°C. Except where mentioned, all chemicals and solutions were purchased from Sigma.
Statistics. Values are expressed as means Ϯ SE of (n) animals. Statistical significance was assumed when pՅ0.05 (t-test or ANOVA).
RESULTS
Characterization of primary cultures of circular smooth muscle cells.
The study of smooth muscle in tissue culture is informative, but commonly used cells that have already undergone adaptation to culture and are already highly proliferative. To date, no study has examined the onset of responsiveness to mitogens in early SMC cultures immediately after isolation, which is relevant to understanding the events of inflammationinduced hyperplasia in vivo. Therefore, in this study a primary culture model was developed to identify and characterize CSMC mitogens.
To develop our culture model, rat colonic CSMC were isolated by enzymatic dissociation similarly to our earlier studies of cellular contractility (38) . This yielded large numbers of long, brightly refractile smooth muscle cells with very high viability (Fig. 1A) . These cells quite rapidly began to shorten and assume a flattened roughly spheroidal appearance as they attached to the culture surface. Over the first 2 days, cell extensions became visible, and a typical ribbon-shaped appearance resulted, as illustrated by repeated imaging over time of a single cell in Fig. 1C . Over the next few days, growth was apparent within the culture wells, with increasing cell number, overlapping cells, and the formation of the typical hill-and-valley appearance of cultured smooth muscle (Fig.  1D) . Immunocytochemistry of these cultures showed uniformly high expression of smooth muscle specific ␣-actin, desmin, and smoothelin, which are markers of the smooth muscle phenotype (Fig. 2) .
Culture purity was a consequence of careful attention to the dissection of small strips of pure circular smooth muscle for subsequent dissociation, which avoided the neurons and gliarich environment of the myenteric plexus. Assessment of glia in primary cultures of CSMC by immunocytochemistry (e.g., Fig. 2F ) showed only a very rare presence, at Ͻ0.01% of cells. The additional possibility of vascular smooth muscle cells in these cultures was assessed by immunocytochemistry for PDGF-R␤ (based on results presented below). PDGF-R␤-positive, smooth muscle specific ␣-actin-positive cells could only very occasionally be found among freshly isolated smooth muscle cells (Fig. 2E) , showing that their presence in subsequent cultures was negligible. Similarly, we assessed the presence of interstitial cells of Cajal using immunocytochemistry for c-kit in freshly isolated cells and primary cultures. Since positive staining was never detected, despite successful staining of positive controls, this implies that these cells failed to survive the isolation process.
To assess the response of CSMC to culture, cell number was measured after trypsinization to free the cells from the culture surface. This showed that CSMC number was roughly constant over the first 3 days in vitro, at 66 Ϯ 18% of initial number by 24 h, and 68.9 Ϯ 24% and 54 Ϯ 8% at 48 and 72 h, respectively. However, this increased to 119 Ϯ 22% by 120 h, evidence of a near doubling in cell number from the number of adhering cells at 24 h (contrast Fig. 1, B and D ; n ϭ 7 separate isolations in each case). Since this likely involved the expression of receptors for growth factors, the response of primary CSMC to mitogens was examined using [
3 H]thymidine incorporation, BrdU incorporation, and immunoblotting.
Primary CSMC proliferation assays. Primary cultures of CSMC were established in 24-well plates and processed for PDGF-BB caused a nearly sixfold increase over control cells, much greater than IGF at either 50 or 100 ng/ml. Data expressed relative to untreated control; *P Ͻ 0.05 vs. untreated control. **P Ͻ 0.05 vs. IGF (100 ng/ml); n ϭ 5 experiments. C: PDGF-AA is ineffective in stimulating [ 3 H]thymidine uptake compared with PDGF-BB (50 ng/ml for each). The response to PDGF-BB was equal to that of FCS, and both were significantly greater than control (n ϭ 3 independent experiments). D: verification of cell number increase at 72 h postmitogen stimulation with either 2.5% FCS (positive control) or growth factors (100 ng/ml), expressed as fold relative to control. PDGF-BB (100 ng/ml; 3.9 nM) nearly doubled cell number, while IGF-1 (100 ng/ml; 13 nM) caused only 35 Ϯ 0.7% increase. EGF and FGF had no effect. (*P Ͻ 0.05 vs. control; **P Ͻ 0.05 vs. IGF-treated cultures; n ϭ 3 independent experiments). increase in [ 3 H]thymidine incorporation (Fig. 3) . Neither PDGF-AA, EGF, nor bFGF induced [ 3 H]thymidine incorporation at any concentration evaluated (Յ100 ng/ml) (Fig. 3, A-C) . PDGF-BB at 5 ng/ml increased [ 3 H]thymidine incorporation significantly, and higher concentrations of 50-100 ng/ml caused similar approximately sixfold increases (Fig. 3B) , similar to the effect of fetal calf serum. IGF-1 was much less effective than PDGF-BB, since IGF-1 at 100 ng/ml induced significant increases in [ 3 H]thymidine incorporation over control of 3 Ϯ 0.6-fold. Cell counts were carried out to confirm the interpretation of the [ 3 H]thymidine incorporation data. This showed that stimulation with either PDGF-BB or IGF-1 increased cell number by 72 h poststimulation, whereas EGF and FGF did not (Fig.  3D) . However, PDGF-BB was more effective than IGF-1, since PDGF-BB (100 ng/ml) induced a 90 Ϯ 16% increase in cell number over control (P Ͻ 0.05), whereas IGF-1 (100 ng/ml) induced only a 35 Ϯ 0.7% increase (P Ͻ 0.05 vs. control; Fig. 3D ).
Cells treated with IGF-1 received greater molarequivalent stimulation than with PDGF-BB in the above experiments, since the molecular weight of IGF-1 is less than that of the other mitogens and in particular PDGF-BB. Repetition of the [ 3 H]thymidine incorporation assays using equimolar concentrations of PDGF-BB and IGF-1 corresponding to 50 and 100 ng/ml of PDGF-BB (2.0 and 3.9 nM, respectively) emphasized the greater response with PDGF-BB than IGF-1; PDGF-BB caused 7.8 Ϯ 1 and 6.3 Ϯ 0.2-fold increases in [ 3 H]thymidine incorporation respectively, whereas the IGF-1 responses were not significantly different from control. Nuclei with positive labeling for BrdU appear yellow (e.g., arrow). All nuclei were nonspecifically stained with Hoechst (blue). F: data showing distribution of BrdUpositive nuclei in control or growth-factor-treated cultures, as illustrated in C-E. The responses to FCS (2.5%) and PDGF-BB were similar to each other and greater than control (*P Ͻ 0.05), while IGF-1 had no significant effect.
We proposed that the appearance of responsiveness to PDGF-BB was an early marker of the onset of CSMC proliferation in vitro. First, we examined the presence of mRNA for the PDGF-R␣ and PDGF-R␤ receptors using reverse-transcription PCR as well as quantitative PCR. This showed that mRNA for PDGF-R␤ was initially scarce but increased more than 20-fold relative to GAPDH by 4 days in culture (Fig. 4) . In contrast, mRNA for PDGF-R␣ was constitutively present and showed no change in adaptation to culture (not shown). Since there was no effect of PDGF-AA (the ligand for PDGF-R␣), further study focused on the role of PDGF-R␤ and the response to PDGF-BB.
Immunocytochemistry for the uptake of BrdU was used to study cell responses at early time points, since these could be scored on a cell-by-cell basis. Primary cultures of CSMC at 4 days postinitiation were exposed to either PDGF-BB or IGF-1 at equal molar concentrations of 2 nM (i.e., 50 ng/ml of PDGF-BB) and subsequently scored for BrdU uptake over a 4-h period commencing 17 h later. Figure 4 , C-F, shows that PDGF-BB caused a large increase in BrDU-positive nuclei that was statistically similar to that of 2.5% FCS, whereas IGF-1 had no significant effect.
These findings show that both PDGF-BB and IGF-1 are mitogens for primary rat CSMC in vitro, whereas PDGF-BB is substantially more potent. Therefore, we evaluated receptor expression and activation, as well as the intracellular responses to each mitogen to look for evidence of the signal transduction responsible for CSM proliferation.
PDGF signaling is active in primary CSMC. Immunocytochemistry was used to examine both onset and localization of PDGF-R␤ expression in primary CSMC. Whereas freshly isolated CSMC showed no staining, a small number of cells were positive for PDGF-R␤ expression by 24 h postisolation (10 Ϯ 0.6%), and the proportion of cells expressing PDGF-R␤ steadily increased over time in culture, with nearly all cells positive by day 7 (92 Ϯ 1.5%). Positive staining was localized to cell membranes and to the perinuclear region of the cytoplasm, creating a distinct outline of the cell extensions (Fig. 5A) .
The appearance of immunoreactivity for PDGF-R␤ expression in vitro correlated with the onset of PDGF-BB-induced cell growth in these cells. Since an early event following PDGF-BB stimulation is the redistribution of its receptor from the cell membrane to the cytoplasm (13), we used immunocytochemistry to test for this in CSMC following exposure to PDGF-BB. CSMC at 10 -12 days in vitro showed PDGF-R␤ expression that was consistently high and uniform, outlining the cell shapes well. By 30 min after addition of PDGF-BB (50 ng/ml), there was redistribution of staining with loss of membrane expression and strong punctate cytoplasmic expression, such that cell outlines were largely lost (Fig. 5, A and B) . Image analysis by quantification of line scans across control or PDGF-stimulated smooth muscle cells showed distinct profiles indicative of a redistribution of PDGF-R␤ away from the cell margins toward the nucleus (Fig. 5, C and D) and suggestive of the onset of signal transduction after internalization of the PDGF-R␤.
Functional expression of the PDGF-R␤ on CSMC was investigated by immunoblotting. First, the outcome of immunoblotting of primary cultures of CSMC on day 7 corroborated the immunocytochemistry by showing strong expression of the 190-kDa PDGF-R␤ (Fig. 5E) . Stimulation with PDGF-BB (50 ng/ml) for 15 min caused the appearance of phosphorylated PDGF-R␤ (pPDGF-R␤; Fig. 5E ), which was absent from control cultures. In addition, cohort cultures showed that both phospho-AKT and phospho-ERK were highly induced by 5 and 15 min poststimulation with PDGF-BB (Fig. 5E) , evidence for activation of these two main signaling cascades downstream of PDGF-R␤ that could be responsible for induced proliferation. Use of the inhibitors PD-98059 and LY-24002 showed that both pathways are crucial to CSMC proliferation, since each inhibitor caused a significant, concentration-dependent reduction in [ 3 H]thymidine uptake ( Fig. 5F ).
High concentrations of IGF-1 required to activate IGF-1-signaling in primary CSMC.
The onset of IGF-1 receptor expression and activation was studied similarly by immunocytochemistry and immunoblotting. Unlike PDGF-R␤ expression, IGF-1-R expression was largely cytosolic at all time points studied in vitro, and stimulation with IGF-1 failed to induce cellular redistribution of IGF-1-R (Fig. 6, A and B) . IGF-1 signaling also involves phosphorylation of its receptor (31) . Addition of IGF-1 (50 ng/ml) for 15 min failed to induce receptor phosphorylation, in line with minimal stimulation of IGF-1-dependent growth stimulation seen above (Fig. 6C) . Control experiments confirmed the detection of pIGF-1R in a positive control (IEC-18 cells) under identical conditions, im- plying a low sensitivity of IGF-1R for its ligand in CSMC under these conditions. Both higher concentrations of IGF-1 and longer times of stimulation were necessary to obtain evidence for IGF-1R phosphorylation in CSMC, whereas 15 min stimulation with 100 ng/ml induced only weak IGF-1R phosphorylation but 30 min stimulation induced a more robust level of IGF-1R phosphorylation (Fig. 6C) .
These multiple lines of evidence showed that IGF-1 signaling was present in primary cultures of CSMC but only weakly active in causing CSMC proliferation compared with the effective signaling and growth stimulation of PDGF-BB on these cells. This suggested a potentially similar and dominant role for PDGF-BB-induced smooth muscle growth in vivo, and this was studied in the rat model of TNBS-induced colitis, where we have described inflammation-induced hyperplasia of the smooth muscle (5) .
PDGF-R␤ expression in vivo. Immunocytochemistry showed that PDGF-R␤ was expressed in all layers of the intestine of control animals, although to greatly varying degrees (Fig. 7A ). In the mucosal layer, strongly immunoreactive cells underneath the epithelium were interpreted to be subepithelial myofibroblasts, and PDGF-R␤ staining was present in both the medial vascular smooth muscle cells and the outer adventitia of the larger blood vessels of the submucosa. However, PDGF-R␤ expression in the smooth muscle layers was limited to only a small proportion of cells, which failed to show colocalization of staining for desmin (e.g., Fig. 7B ), and thus were not intestinal smooth muscle cells. Dual-label immunocytochemistry showed that this PDGF-R␤ labeling was closely associated with an endothelial marker, PECAM, present on the small blood vessels in the smooth muscle layer (Fig. 7C) . This was particularly evident in whole mount preparations of the circular smooth muscle layer, where PDGF-R␤-positive vascular cells were seen in close association with PECAM-positive endothelial cells and could be identified as pericytes (Fig. 7C, inset) . In sections of the colon, the majority of PDGF-R␤-positive cells in the smooth muscle tissue showed similar close, but nonoverlapping, association with dual labeling for PECAM expression, with only a small proportion of cells expressing PDGF-R␤ alone, possibly due to the exclusion of the remainder of the vessel from the section.
While few or no intestinal smooth muscle cells expressed PDGF-R␤ in the control colon (Fig. 7A) , induction of colitis by mucosal application of TNBS caused a rapid and obvious increase in staining of PDGF-R␤-positive intestinal smooth muscle cells by day 4 (Fig. 8A) . Quantification showed that more than 20% of cells were PDGF-R␤ positive by 6 h, increasing to 30% by day 4 (Fig. 8B) . To address the possible contribution of angiogenesis to this increase, dual-label immunocytochemistry and confocal microscopy were used to show the relative distributions of PDGF-R␤ and PECAM immunoreactive cells (Fig. 8C) . This consistently showed that the great Fig. 7 . Immunocytochemistry for the presence and distribution of PDGF-R␤ in the middescending colon of the control rat. A: fluorescence micrograph showing expression of PDGF-R␤ (bright areas) is expressed in all layers of the control colon. In the smooth muscle layer, PDGF-R␤ is expressed on a small proportion of cells (arrow). There is strong labeling in the mucosa of subepithelial myofibroblasts (e.g., arrows) and of blood vessels in the submucosa (e.g., asterisk). In the smooth muscle layers, there were small numbers of dispersed positive cells (arrowhead). Scale bar, 110 m. B: higher magnification images of smooth muscle layers of control colon after staining for PDGF-R␤ (red) and for the differentiated smooth muscle marker, desmin (green) showing lack of colocalization within the circular smooth muscle layer (note arrows). Scale bar, 90 m. C: proximity of staining of PDGF-R␤ (green) with the endothelial marker, PECAM (red). In the submucosa, larger blood vessels were identified with strongly PECAM-positive endothelial cells (arrows) and PDGF-R␤ expression on both the vascular smooth muscle cells and the outer adventitia. In the smooth muscle layers, PECAM was expressed on smaller blood vessels (lower arrows) in close proximity to PDGF-R␤, with PDGF-R␤ immunoreactivity rarely observed alone (e.g., arrowhead). majority of PDGF-R␤-positive CSMC occurred independently of PECAM-labeling, implying a lack of contribution of vascular smooth muscle.
The increase in PDGF-R␤ expression correlated well with the presence of ISMC hyperplasia in this model, where increased SMC number is first observed by day 2 and is increased by day 4 but complete with no further proliferation by day 6 (25) . Mitogenic signaling should therefore appear early and might match with the appearance of PDGF-R␤ over this time course. This was examined in small strips of circular smooth muscle, which were taken from either control or day 2 animals as described for the establishment of the culture model above and subjected to enzymatic dissociation. The resulting cell suspensions were briefly stimulated (15 min) with IGF-1, PDGF-BB, or vehicle before homogenizing and immunoprecipitation using the IGF-1-R or PDGF-R␤ antibody.
Immunoblots showed no expression of PDGF-R␤ in control freshly isolated CSMC but strong expression in CSMC isolated on day 2 of colitis ( Fig. 9A ), in agreement with data for immunocytochemistry in vivo. Furthermore, stimulation with PDGF-BB (100 ng/ml for 15 min) caused the appearance of pPDGF-R␤ in CSMC from the inflamed colon but not the control colon, showing functional expression of its receptor in these isolated CSMC. As expected, the positive control of primary cultured CSMC showed robust expression of pPDGF-R␤ following exposure to PDGF-BB, since these cells showed a strong growth response to this stimulus. In contrast, IGF-1-R was detected in roughly similar amounts in CSMC from either the control or inflamed colon (Fig. 9B) , and there was no detectable expression of pIGF-1-R in unstimulated CSMC from the control or inflamed colon. Moreover, application of IGF-1 (100 ng/ml) did not induce pIGF-1-R in these isolated CSMC. This is interpreted as evidence that inflammation causes the expression of functional PDGF-R␤ in circular smooth muscle. This may represent the major mechanism for the hyperplasia of ISMC that occurs early in the inflamed colon. 
DISCUSSION
In the normal intestine, ISMC are contractile, nonproliferating cells. However, inflammation changes many aspects of ISMC physiology such as their contractile properties (38) and for a substantial number of cells, causing a reentry into the cell cycle that gives rise to significant increases in tissue mass (5; 25) . While hyperplasia and altered cellular contractility will contribute to altered tissue and organ function during inflammation, these linked processes could be part of a lasting/ persistent challenge to intestinal motility, with effects such as increased tissue mass that remain following resolution. With repeated inflammatory episodes, like those characteristic of Crohn's disease, alterations of cellular number and nature may lead to intestinal obstruction and stricture formation (37) .
The reasons for the onset of growth of smooth muscle in the inflamed intestine are not understood, although well characterized in other systems. For example, the onset of intimal hyperplasia in the vasculature due to endothelial damage involves the loss of endothelial nitric oxide-mediated growth inhibition at the same time as exposure to serum-derived mitogens (reviewed in Ref. 3) . Knowledge of the inhibitory influences on growth of ISMC in vivo is also limited, but there is evidence for an inhibitory intrinsic neural input (4, 26, 29) as well as extracellular matrix-mediated mechanisms (3). These could give insight into understanding of the shift in the balance toward cell growth that in the well-defined model of TNBScolitis is evident by 48 h and complete by day 6 (25) . To study this, we developed a tissue culture model using freshly isolated circular SMC that allows study of the onset of responsiveness to potential mitogens in the period immediately following enzymatic isolation.
CSMC were isolated from the normal colon similarly to those studied earlier for their contractile properties, which showed highly reproducible elevations of intracellular Ca 2ϩ and contractile responses to acetylcholine and serotonin (38, 39) . In the present study, these cells were followed in primary culture as they attached to the culture surface and became responsive to exogenous mitogens. Adaptation to culture was successful for a high proportion of the initial cells, which then uniformly displayed markers of smooth muscle phenotype, reasons for confidence that the outcomes from their study are representative of the cell population, and not of a small founder subset. In addition, the use of thin strips of circular smooth muscle tissue to derive these cultures was essential in enabling their subsequent relative purity, with minimal presence of interstitial cells, enteric glia, neurons, and vascular smooth muscle.
Initial work focused our attention on PDGF-BB and IGF-1, since other mitogens were inactive. While CSMC in vitro acquired widespread expression of receptors for both PDGF and IGF-1, multiple lines of evidence showed that PDGF-BB was a far more potent stimulus for growth. This was evident in assays of BrdU incorporation at early times, subsequent [ 3 H]thymidine incorporation, by direct cell counting, and by evaluation of receptor phosphorylation. This showed that CSMC could respond sensitively to PDGF-BB as a mitogen, although no evidence for expression of PDGF-R␤ was seen in vivo or initially in vitro. However, CSMC both in the inflamed colon and after their isolation in vitro showed high levels of PDGF-R␤ expression as well as PDGF-BB-induced receptor phosphorylation. Since the response to IGF-1 in those cells remained relatively weak, PDGF-BB derived from platelet activation could be the main driving factor for CSMC hyperplasia early in colitis with the initiation of transcription and expression of PDGF-R␤ governing responsiveness to this factor (whereas IGF-R is continuously present). However, we caution that events of inflammation in vivo may be complicated by the presence of multiple growth factors, cytokines, and binding proteins as well as alterations to extracellular matrix.
While earlier studies using human ISMC confirmed that IGF-1 can be mitogenic in vitro, with 100 nM (equivalent to 765 ng/ml) causing the maximal response of doubling of [ 3 H]thymidine uptake (17, 18) , the actions of IGF-1 that lie outside of a mitogenic role may be critical in understanding its importance to the ISMC. Recently, Hazelgrove et al. (12) showed that the ISMC on day 7 of TNBS colitis represent an altered phenotype, one in which there is a significantly increased level of endogenous phosphorylation of the IGF-1R driven by IGF-1 production and autocrine stimulation. Since Fig. 9 . CSMC from the acutely inflamed intestine of the rat are responsive to PDGF but not IGF-1. CSMC were isolated from control rats or at 2 days of TNBS-induced colitis and incubated with either PDGF-BB, IGF-1 (100 ng/ml; ϩ) or vehicle. After immunoprecipitation with the PDGF-R␤ or IGF-R antibody, samples were immunoblotted using pPDGF-R␤ and PDGF-R␤ or pIGF-R and IGF-R antibodies, respectively. Outcomes are representative of at least 3 independent experiments. A: representative immunoblots showing that freshly isolated control CSMC did not express PDGF-R␤, and no pPDGF-R␤ was detected after stimulation. However, freshly isolated TNBS day 2 CSMC expressed PDGF-R␤ as well as phosphorylated PDGF-R␤ that was markedly increased with stimulation by PDGF-BB. Primary CSMC (i.e., cultured to confluence) were used as a positive control. B: representative immunoblots showing that IGF-1R was expressed in CSMC from both control rats and at day 2 of colitis without detectable baseline phosphorylation. Appearance of pIGF-1R did not increase with stimulation of CSMC from the inflamed colon by IGF-1 (100 ng/ml), although a strong response was detected in the positive control of primary CSMC (i.e., confluent cultures).
IGF-1 is upregulated in Crohn's disease (32, 43) and IGF-1 can promote extracellular matrix deposition by ISMC after extended culture (40) as well as cause ␣-V-␤3 integrin-dependent cell growth (17) and migration (8) , this may have significant consequences in vivo. Specifically, it is possible that the initial onset of hyperplasia (leading to upregulated expression of largely cytosolic IGF-R as shown here) represents the framework for subsequently increased IGF-1 signaling efficiency that can be realized with either protracted cell division in vitro or with repeated inflammatory events in vivo. This is in keeping with our understanding of the events leading to intestinal stricture formation in human Crohn's disease as well as in the sporadic strictures that we described in TNBS colitis (26) .
The pathology of liver fibrosis shows a close parallel with the changes in CSMC seen here, since PDGF is the most potent proliferative factor and liver stellate cells gain expression of PDGF-R␤ upon activation (reviewed in Ref. 66). In liver fibrosis, increased levels of PDGF-BB are derived from infiltrating macrophages (1, 14) , which may also occur in the inflamed intestine. For example, elevated levels of PDGF-BB have been described in both serum and biopsy samples in IBD (16, 33) , where both PDGF-BB and PDGF-R␤ may be present in inflamed intestinal regions (20) . However, the permissive events that regulate the early onset of growth factor receptor expression and CSMC hyperplasia as well as their subsequent downregulation remain poorly understood. Multiple factors are likely involved, such as damage to the enteric nervous system that coincides with hyperplasia and can indicate loss of an inhibitory input (25, 29) , pro-inflammatory cytokines from resident and infiltrating immune cells as well as the actions of immune cell-derived proteases on extracellular matrix factors that may interfere with critical integrin receptor signaling (17) . Thus evidence for PDGF-BB as a major pro-mitotic factor in vitro and in vivo, while useful in understanding the process of hyperplasia, requires study of earlier events and a more complete understanding of these before evolution of a strategy for control of unwanted ISMC growth in either animal models or in human disease.
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